Effective Dose of Escitalopram in Moderate versus Severe DSM-IV Major Depression

Introduction: Data from the three available placebo-controlled trials with fixed doses of escitalopram in the acute therapy of DSM-IV major depressive disorder (MDD) were pooled. The hypothesis tested was that escitalopram 10 mg/d might be an effective dose in moderate MDD, whereas escitalopram 20 mg/d might be needed in severe depression. Methods: The Montgomery-Asberg Depression Scale with all 10 items was used at baseline to differentiate between moderate (score range 22 to 29) and severe (scores ≥ 30) major depression. The MADRS₆ was selected as the primary efficacy parameter, using a standardised effect size of 0.40 as indicator of clincally significant response. Results: After 8 weeks of therapy, escitalopram 10 mg was superior to placebo, with a standardised effect size above 0.40 for patients with moderate depression, but not for those with severe depression. In contrast, 20 mg escitalopram was superior to placebo, with a standardised effect size above 0.40 in severe depression, but not in moderate depression. The MADRS₆ showed response (standardised effect sizes above 0.40) for moderate depression after two weeks of treatment with 10 mg escitalopram and in severely depressed patients after 4 weeks with 20 mg escitalopram. Conclusion: Escitalopram 10 mg/d was the optimal dose for the treatment of moderate DSM-IV MDD, while escitalopram 20 mg/d was an effective dose in patients with moderate to severe depression.

References

• 1 American Psychiatric A ssociation. Diagnostic and statistical manual of mental disorders. Fourth edition (DSM-IV). Washington DC; American Psychiatric Association 1994
• 2 Bagby R M, Ryder A G, Schuller D R, Marshall M B. The Hamilton Depression Rating Scale: Has the gold standard become a lead weight?.  Am J Psychiatry. 2004;  161 2163-2177
• 3 Barbui C, Hotopf M. Amitryptiline v the rest: still the leading antidepressant after 40 years of randomised clinical trials.  Br J Psychiatry. 2001;  178 129-144
• 4 Bech P, Cialdella P, Haugh M, Birkett M A, Hours A, Boissel J P, Tollefson G D. A meta-analysis of randomised controlled trials of fluoxetine versus placebo and tricyclic antidepressants in the short-term treatment of major depression.  Br J Psychiatry. 2000;  176 421-428
• 5 Bech P, Tanghøj P, Cialdella P, Friis A H, Pedersen A G. Escitalopram dose-response revisited: an alternative psychometric approach to evaluate clinical effects of escitalopram compared to citalopram and placebo in patients with major depression.  Int J Psychopharmacol. 2004;  7 283-290
• 6 Bech P. Pharmacological treatment of depressive disorders: A review. In: Maj M, Sartorius N. (eds) Depressive disorders in psychiatry. Chichester; Wiley, second edition 2002
• 7 Bulpitt C J. Medical statistics: meta-analysis.  Lancet. 1988;  2 93-94
• 8 Burke W J, Gergel I, Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients.  J Clin Psychiatry. 2002;  63 331-336
• 9 Chen F, Larsen M B, Sánchez C, Wiborg O. The S-enantiomer of R,S-citalopram, increases inhibitor binding to the human serotonin transporter by an allosteric mechanism. Comparison with other serotonin transporter inhibitors.  European Neuropsychopharmacology. 2005;  15 193-198
• 10 Cohen J. Statistical power analysis for the behavioural sciences. Mahwah, NJ; Lawrence Erlbaum 1988
• 11 Colonna L, Reines E H, Andersen H F. A randomized, double-blind, 24-week study of escitalopram (10 mg/day) versus citalopram (20 mg/day) in primary care patients with major depressive patients with major depressive disorder.  Curr Med Res Opin. 2005;  21 1659-1668
• 12 Demyttenaere K, Mesters P, Boulanger B, Dewe W, Delsemme M H, Gregoire J, Van Ganse E. Adherence to treatment regimen in depressed patients treated with amitriptyline or fluoxetine.  J Affect Disord. 2001;  65 243-252
• 13 Fabre L F, Abuzzahab F S, Amin M, Claghorn J L, Mendels J, Petrie W M. et al . Sertraline safety and efficacy in major depression: a double-blind fixed-dose comparison with placebo.  Biol Psychiatry. 1995;  38 592-602
• 14 Faries D, Herrera J, Rayamajhi J, DeBrota D, Demitrack M, Potter W Z. The responsiveness of the Hamilton Depression Rating Scale.  J Psychiatr Res. 2000;  34 3-10
• 15 Gorman J, Korotzer A, Su G. Efficacy Comparison of escitalopram and citalopram in the treatment of major depressive disorder: pooled analysis of placebo-controlled trials.  CNS Spectr. 2002;  7 (4 Suppl 1) 40-44
• 16 Gram L F. Fluoxetine.  N Eng J Med. 1994;  331 1354-1361
• 17 Kragh-Sorensen P, Hansen C E, Baastrup P C, Hvidberg E F. Self-inhibiting action of nortryptilin’s antidepressive effect at high plasma levels.  Psychopharmacologia. 1976;  45 306-312
• 18 Lepola U M, Loft H, Reines E H. Escitalopram (10-20 mg/day) is effective and well tolerated in a placebo-controlled study in depression in primary care.  Int Clin Psychopharmacol. 2003;  18 211-217
• 19 Licht R W, Qvitzau S, Allerup P, Bech P. Validation of the Bech-Rafaelsen Melancholia Scale and the Hamilton Depression Scale in patients with major depression: is the total score a valid measure of illnes severity?.  Acta Psychiatr Scand. 2005;  111 144-199
• 20 Mittmann N, Mitter S, Borden E K, Herrmann N, Naranjo C A, Shear N H. Montgomery-Asberg severity gradations.  Am J Psychiatry. 1997;  154 1320-1321
• 21 Moncrieff J, Kirsch I. Efficacy of antidepressants in adults.  BMJ. 2005;  331 155-157
• 22 Moncrieff J. Are antidepressants overrated? A review of methodological problems in antidepressant trials.  J Nerv Ment Dis. 2001;  189 288-295
• 23 Montgomery S A, Asberg M. A new depression scale designed to be sensitive to change.  Br J Psychiatry. 1979;  134 382-389
• 24 Müller M J, Szegedi A, Wetzel H, Benkert O. Moderate and severe depression. Gradations for the Montgomery-Asberg Depression Rating Scale.  J Affect Disord. 2000;  60 137-140
• 25 Ninan P T, Ventura D, Wang J. Escitalopram is effective and well tolerated in the treatment of severe depression. Data presented at the 156th Annual Meeting of the American Psychiatric Association, 17 - 22 May 2003, San Francisco, CA. Further details available at http://www.forestclinicaltrials.com/CTR/CTRController/CTRViewPdf?_file_id= scsr/SCSR_SCT-MD-26_final.pdf. 
• 26 Olsen R L, Mortensen E L, Bech P. Prevalence of major depression and stress indicators in the Danish general population.  Acta Psychiatr Scand. 2004;  109 96-103
• 27 O’Sullivan R L, Fava M, Augustin C, Baer L, Rosenbaum J F. Sensitivity of the six-item Hamilton Depression Rating Scale.  Acta Psychiatr Scand. 1997;  95 379-384
• 28 Peto R. Why do we need systematic overviews of randomised trials.  Stat Med. 1987;  6 233-244
• 29 Preskorn S H. Recent dose-effect studies regarding antidepressants. In: Balant LP, Benitez J, Dahl SG. (eds) Clinical pharmacology in psychiatry: finding the right dose of psychotropic drugs. Brussels; European Commission 1998: pp 45-61
• 30 Reisby N, Gram L F, Bech P, Sihm F, Krautwald O, Elley J, Ortmann J, Christiansen J. Clomipramine: Plasma levels and clinical effects.  Communications in: Psychopharmacology. 1979;  3 341-351
• 31 Rifkin A. SSRI optimal dose remains at issue.  J Clin Psychiatry. 1997;  58 87-88
• 32 Sánchez C, Bøgesø K P, Ebert B, Reines E H, Braestrup C. Escitalopram versus citalopram: the surprising role of the R-enantiomer.  Psychopharmacology. 2004;  174 163-176
• 33 Schmid J E, Koch G, La Vange L M. An overview of statistical issues and methods of meta-analyses.  J Biopharm Stat. 1991;  1 103-120
• 34 Stein D J, Andersen H F, Goodman W K. Escitalopram for the treatment of GAD: Efficacy across different subgroups and outcomes.  Ann Clin Psychiatry. 2005;  17 71-75
• 35 Wade A, Lemming O M, Hedegaard K B. Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.  Int Clin Psychopharmacol. 2002;  17 95-102
• 36 World Health O rganisation. International Classification of Diseases, tenth revision (ICD-10). Diagnostic criteria for research. Geneva; World Organisation; Geneva 1993